Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
BUTABARBITAL SODIUM TABLETS | Identification, Infrared Absorption <197K> | USP36–NF31 | 2716 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5 of Test specimen: Change Proceed as directed for Column Partition Chromatography under Chromatography <621>, packing the chromatographic tube as follows. to: Pack a chromatographic tube as follows. |
OCTOCRYLENE | Identification, Ultraviolet Absorption <197U> | USP36–NF31 | 4557 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4: Change Absorptivities, calculated on the as-is basis, to: Absorptivity at 303 nm, calculated on the as-is basis, |
EGG PHOSPHOLIPIDS | ASSAY/Content of Phospholipids | USP36–NF31 | 2000 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Solution A: Change acetic acid to: glacial acetic acid AND Line 2 of Solution B: Change acetic acid to: glacial acetic acid |
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES | Assay | USP36–NF31 | 3276 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 4/Instrumental conditions | USP36–NF31 | 4509 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Cell: Change 0.5 cm to: 1 cm |
BACLOFEN | ASSAY/Procedure/Chromatographic system | First Supplement to USP36–NF31 | 5951 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column: Change 250-cm to: 25.0-cm |
POLYSORBATE 80 | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2163 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
OXCARBAZEPINE | IMPURITIES/Organic Impurities, Procedure 2 | First Supplement to USP36–NF31 | 6035 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 9 of Column 1 of Table 3: Change Oxcarbazepine related compound Eg to: Oxcarbazepine related compound E AND Delete footnote g |
GLYCERYL DISTEARATE | ASSAY/Procedure/Chromatographic system | USP36–NF31 | 2029 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column temperature: Change Column temperature: 40° to: Temperatures Detector: 40° Column: 40° |
CAFFEINE CITRATE INJECTION | Assay | USP36–NF31 | 2732 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Chromatographic system: Change 150-cm column to: 15-cm column |
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION | Identification | USP36–NF31 | 4652 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the Identification test under Oxymetazoline Hydrochloride Nasal Solution. to: Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of… Read More |
ETHYL OLEATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2006 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Change: and to: or |
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION | Assay | USP36–NF31 | 3276 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
OLMESARTAN MEDOXOMIL | IMPURITIES/Organic Impurities/Impurity Table | USP36–NF31 | 4570 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More |
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities, Procedure 2 | First Supplement to USP36–NF31 | 5996 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3: Change the section head Isosorbide mononitrate related compound A stock solution: to: Isosorbide mononitrate related compound A standard stock solution: AND Line 7: Change the section head Isosorbide dinitrate stock solution: to: Isosorbide… Read More |
POTASSIUM METAPHOSPHATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2172 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
<232> ELEMENTAL IMPURITIES—LIMITS | DRUG PRODUCTS/Options for Demonstrating Compliance | USP36–NF31 | 151 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 17 of Summation Option: Change the manufacturer must validate to: the manufacturer must ensure |
SODIUM HYDROXIDE | ASSAY/Procedure | USP36–NF31 | 2203 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change = volume of Titrant consumed by the Sample to the first endpoint (mL) to: = volume of Titrant consumed by the Sample to the second endpoint (mL) |
CAFFEINE CITRATE ORAL SOLUTION | Assay | USP36–NF31 | 2733 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Chromatographic system: Change 150-cm column to: 15-cm column |
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION | Assay | USP36–NF31 | 3277 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
POLYVINYL ALCOHOL | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913> | USP36–NF31 | 4830 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change and to: or |
FERROSOFERRIC OXIDE | IMPURITIES | USP36–NF31 | 2018 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample solution C in Limit of Lead (Pb): Change Sample solution to: Sample stock solution AND Line 1 of Sample solution D in Limit of Lead (Pb): Change Sample solution to: Sample stock solution AND Line… Read More |
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 5438 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More |
LOPINAVIR AND RITONAVIR TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP36–NF31 | 6005 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Tolerances: Change 80.0% to: 80% |
SORBITAN MONOLAURATE | IDENTIFICATION/A. | USP36–NF31 | 2212 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 260–280 to: 260–280 on 1-g sample |
<232> ELEMENTAL IMPURITIES—LIMITS | ANALYTICAL TESTING | USP36–NF31 | 151 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change If, by validated processes and supply-chain control, to: If, by process monitoring and supply-chain control, |
AMOXICILLIN | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 2477 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Acceptance criteria: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the Standard solution. ] to: [Note—The reporting limit is 0.03 times the amoxicillin peak from the Standard solution. ] |
CARISOPRODOL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS | USP Reference standards <11> | USP36–NF31 | 2813 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of USP Codeine N-Oxide RS: Change C18H21O4 to: C18H21NO4 |
EDETATE DISODIUM | ASSAY/Procedure | USP36–NF31 | 3370 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5: Delete Titrimetric system (See Titrimetry <541>.) Mode: Direct titration Titrant: 0.1 N sodium hydroxide VS Endpoint detection: Visual |
QUININE SULFATE | IMPURITIES/Dihydroquinine Sulfate | USP36–NF31 | 4995 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5 of Analysis: Change Result = (rU/rS) × 100 to: Result = rU/(rU + rS) × 100 |
GLYCERYL MONOLINOLEATE | ASSAY/Procedure | USP36–NF31 | 2030 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 13 of Chromatographic system: Change Column temperature: 40° to: Temperatures Detector: 40° Column: 40° |
VENLAFAXINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5551 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
QUININE SULFATE TABLETS | ASSAY/Procedure | First Supplement to USP36–NF31 | 6046 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4 of Analysis: Change dihydroquinone sulfate to: dihydroquinine sulfate |
SORBITAN MONOOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
ACETYLTRIBUTYL CITRATE | IDENTIFICATION/B. | USP36–NF31 | 1869 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change USP Acetyltriethyl Citrate RS to: USP Acetyltributyl Citrate RS |
BETAMETHASONE SODIUM PHOSPHATE | Identification/B. Thin-Layer Chromatographic Identification Test <201> | USP36–NF31 | 2645 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test solution: Change 1 mg per mL. to: 1 mg per mL in methanol. |
CLAVULANATE POTASSIUM | IMPURITIES/Organic Impurities/Procedure 3: Limit of Aliphatic Amines | USP36–NF31 | 3022 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | In the definition list in Analysis: Change CU = nominal concentration of Clavulanate Potassium in the Standard solution to: CU = nominal concentration of Clavulanate Potassium in the Sample solution |
EDETATE DISODIUM | ASSAY/Procedure | USP36–NF31 | 3370 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 16 of Analysis: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of Analysis: Change Result = (VT/VU) × W × (Mr1/Mr2) ×… Read More |
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS | Assay for rifampin, isoniazid, and pyrazinamide | USP36–NF31 | 5047 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 12 of Procedure: Change the Standard preparation and the Assay preparation, respectively. to: the Assay preparation and the Standard preparation, respectively. |
HYDROXYETHYL CELLULOSE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2038 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
VENLAFAXINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5554 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
BETHANECHOL CHLORIDE | IMPURITIES/Heavy Metals, Method 1 <231> | Second Supplement to USP36–NF31 | 6568 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test preparation: Change Bethacholine Chloride to: Bethanechol Chloride |
SORBITAN MONOPALMITATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 210–225 to: 210–225 on 1-g sample |
ETHYLCELLULOSE DISPERSION TYPE B | ASSAY/Procedure | USP37–NF32 | 5981 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 3 of Analysis: Change Calculate the percentage of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: to: Calculate the percentage of the labeled amount of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: |
CEFADROXIL | ASSAY/Procedure | First Supplement to USP37–NF32 | 6602 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 3 of Sample solution: Change USP Cefadroxil RS to: Cefadroxil |
DACARBAZINE | USP Reference standards <11> | USP37–NF32 | 2504 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 3 of USP Dacarbazine Related Compound B RS: Change C4H3N5O 137.10 to: C4H3N5O · H2O 155.12 |
CEFTRIAXONE INJECTION | Assay | USP37–NF32 | 2241 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Change pH 7.0 Buffer, pH 5.0 Buffer, Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Prepare as directed in the Assay under Ceftriaxone Sodium. to: pH 7.0 Buffer—Dissolve 13.6 g of dibasic… Read More |
STERILE WATER FOR INHALATION | CHEMICAL INFORMATION | USP37–NF32 | 5174 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Add the chemical formula and molecular weight: H2O 18.02 |
LEVODOPA | IMPURITIES | USP37–NF32 | 3533 | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Row 6 of Column 1 of Table 1: Change 1-Veratrylglycine to: L-Veratrylglycinea AND Add a footnote: a3-(3,4-Dimethoxyphenyl)-L-alanine. |
CHLORPHENIRAMINE MALEATE | IMPURITIES/Organic Impurities | First Supplement to USP37–NF32 | 6617 | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 1 of Standard solution: Change 1.1 μg/mL of USP Chlorpheniramine Maleate RS in Diluent, to: 1.4 μg/mL of USP Chlorpheniramine Maleate RS in Diluent, |